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Summary. Hepatitis C Virus (HCV) infection is major health problem worldwide, with 150 million infected 
people according to recent epidemiologic estimations. The introduction of direct-acting antivirals made a 
revolutionary change in the management of HCV infected patients with surprisingly high rates of antiviral 
response, improved tolerability and reduced time of treatment. Sofosbuvir, in combination with different part-
ner drugs, has been the molecule that led this incredible change. The last generation of SOF-based regimens, 
namely Sofosbuvir/Velpatasvir, represents a single tablet, once a day, pangenotypic and pan-fibrotic combina-
tion, demonstrated to be safe and effective in almost all type of HCV infected individuals. This review over-
views the main clinical data of SOF/VEL registration trials, underlying the key features of this combination 
in terms of efficacy, safety and Patients Reported Outcomes obtained in more than 1800 HCV chronically 
infected subjects. (www.actabiomedica.it)
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Introduction
150 million people are infected worldwide by the 
Hepatitis C Virus (HCV), which is a single stranded 
RNA virus from the Flaviviridae family with 6 ma-
jor genotypes (GTs) (1, 2). Progressive liver fibrosis is 
caused by chronic HCV infection, which can induce 
cirrhosis, hepatic decompensation, and hepatocellular 
carcinoma. It is estimated that the annual mortality 
rate of half a million people is due to liver disease as-
sociated with chronic HCV infection (3). 
An estimated 35% of global HCV infections are 
caused by HCV GTs 2 and 3, which affect roughly 58 
million people (4). Contrary to GT1, GTs 2 and 3 are 
diffused in low-income regions such as Latin America, 
Asia, sub-Saharan Africa and Eastern Europe. HCV 
GTs 2 and 3 were categorized together in treatment 
guidelines and were classified as easy to treat geno-
types before the introduction of direct-acting antiviral 
agents (4). According to recent studies, HCV GT3 is 
linked to rapid disease progression and has lower rates 
of response to treatment compared to GT2, as particu-
larly demonstrated in patients with cirrhosis and in pa-
tients who have not reacted to earlier treatment (5, 6). 
Patients with decompensated cirrhosis caused by 
HCV chronic infection is set to rise in the next decade 
(3). Liver transplantation was the only treatment op-
tion available to these patients until recently.
An additional challenge for clinicians is the 
eradication treatment in the HCV/HIV co-infected 
population (7). In fact, HCV/HIV-coinfected patients 
suffer from higher rates of cirrhosis and liver decom-
pensation disease than their mono-infected counter-
parts  (8).
HCV treatment has recently undergone a trans-
formation with the development of drugs that directly 
impede HCV replication. Effective combinations of 
direct-acting antiviral agents are currently available. 
Clinicians must consider the patient’s treatment his-
tory, HCV GT and subtype, stage of fibrosis, and pat-
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terns of antiviral resistance in specific cases in order to 
select a suitable regimen. 
Regimens which include ribavirin (RBV) show 
a higher rate of side effects, mainly hematologic and 
RBV-free combinations would allow a better manage-
ment of a wider range of patients, including those with 
a low tolerance to RBV. This would in turn minimize 
the necessity for pretreatment testing and monitoring 
during therapy, aspects that could be especially benefi-
cial in low-income countries. 
Sofobusvir (SOF) is a nucleotide analogue inhibi-
tor of the HCV NS5B polymerase approved for HCV 
treatment in conjunction with other agents, which 
include NS5A inhibitors, NS3/4A protease inhibi-
tors (PI), RBV, and peginterferon-RBV. Velpatasvir 
(VEL) (also formerly known as GS-5816, Gilead Sci-
ences) with antiviral activity against HCV replicons in 
GTs 1 to 6, is a last generation, pan-genotypic HCV 
NS5A inhibitor.
The SOF/VEL is a single tablet, once a day regi-
men that combines two pan-genotypic, high potency 
and high genetic barrier antiviral molecules, provid-
ing >95% of SVR across all GTs with favourable safety 
and tolerability across a broad patient population even 
for decompensated cirrhotic subjects. 
The SOF/VEL pill is PI, gluten, and lactose free 
and can be used without RBV to address unmet needs 
in the HCV treatment paradigm.
ASTRAL studies
An evaluation of efficacy and safety on the com-
bination of sofosbuvir and velpatasvir was reported 
in different patient populations by a series of Phase 
III clinical trials entitled ASTRAL (ASTRAL-1, 
ASTRAL-2, ASTRAL-3, ASTRAL-4, and AS-
TRAL-5) (9-12) (Figure 1).
The ASTRAL studies demonstrated that SOF/
VEL is highly effective across all GTs and different 
stages of liver damage, and can therefore be defined 
as a pan-genotipic and pan-fibrotic regimen. The fol-
lowing ASTRAL studies were focused on particular 
patient settings, providing information with regard to 
the efficacy and safety of SOF/VEL in subpopulations 
of HCV-positive subjects, which were considered as 
difficult to treat until now.
ASTRAL populations and study design
ASTRAL-1 included patients infected with 
HCV GTs 1 to 6 with different stages of liver dam-
age up to compensated cirrhosis, with the exclusion of 
GT3 infected patients (9). In the current DAA therapy 
era, GT3 infection has been relatively difficult to treat 
compared to other GTs, especially in subjects with 
cirrhosis or prior HCV treatment failure; therefore, a 
dedicated clinical trial study was set-up for those in-
fected with GT3.
Patients were enrolled at 81 sites in North Amer-
ica, Europe, and Hong Kong. The study was double-
blinded and placebo-controlled. Patients were rand-
omized 5:1, with the exclusion of 35 patients infected 
with GT5, who only underwent SOF/VEL therapy, 
which was attributed to the low number. A total of 624 
patients received at least one dose of the drug (116 pa-
tients received a placebo), 121/624 had compensated 
cirrhosis and 201/624 had experienced treatment.
The results of ASTRAL-2 and ASTRAL-3 stud-
ies are reported in the same manuscript (10), focused 
on HCV GT2 and HCV GT3 infected populations 
respectively. As mentioned in the introduction section, 
these two GTs, previously considered as easy to treat in 
the IFN-era, showed lower SVR rates for DAA-based 
therapies (5, 6).
ASTRAL-2 and ASTRAL-3 studies shared 
identical inclusion/exclusion criteria, and about 20% 
of patients with compensated cirrhosis were enrolled. 
Patients who underwent previous treatment were also 
included (20%/total). Subjects with decompensated 
cirrhosis and those who interrupted previous therapy 
as a result of adverse events were excluded. Patients 
were randomized 1:1 in both of the studies, in order to 
receive different SOF/VEL-based regimens (12 weeks 
with or without RBV in ASTRAL-2, 12 weeks or 24 
weeks without RBV in ASTRAL-3). ASTRAL-2, 
enrolled 266 patients to initiate treatment from 51 
sites in the United States while in ASTRAL-3, 552 
patients from centers in North America, Europe, and 
Australia initiated therapy.
ASTRAL-4 was dedicated to naïve and experi-
enced HCV patients with decompensated cirrhosis 
(CHILD-Pugh-Turcotte class B) (11). The study en-
rolled patients who did not receive a liver transplanta-
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tion, or undergo antiviral treatment with any NS5A 
or NSB inhibitors, with a platelet count higher than 
30,000/mm3 and a creatinine clearance higher than 50 
ml/min (Cockcroft-Gault equation). A total of 267 
patients, recruited from 47 sites in the United States, 
initiated treatment with the following randomization: 
90 patients received SOF/VEL for 12 weeks, 87 re-
ceived SOF/VEL plus RBV for 12 weeks and 90 re-
ceived SOF/VEL for 24 weeks. All of the HCV GTs 
except for GT 5 were represented.
Finally, to assess SOF/VEL efficacy and safety in 
HCV patients coinfected with HIV-1, ASTRAL-5, 
an open-label, single arm study, was performed (12). 
Patients were enrolled from 17 centers in the United 
States, and were required to be treated with an approved 
antiretroviral regimen, to acquire a HIV-1 viremia low-
er than 50 copies/mL and a CD4+ T-cell count higher 
than 100 cells/mL. Patients with compensated cirrho-
sis were also included, as well as experienced patients 
(excluding prior NS5A and NS5B inhibitors).
Figure 1. ASTRAL study design.
Legend: SOF: Sofosbuvir; VEL: Velpatasvir; RBV: Ribavirin; GT: genotype; TN: Treatment Naive; TE: Treatment Experienced; 
NC: Non Cirrhotic; CC: Compensated Cirrhosis; CTP-B Cirrhosis: Child-Turcotte-Pugh B Cirrhosis. 
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One hundred and six co-infected subjects initi-
ated therapy consisting of a single pill of SOF/VEL 
once a day for 12 weeks (with the identical regimen 
and length for all the enrolled patients). 
Efficacy across ASTRAL studies
The primary efficacy endpoint was common in all 
the ASTRAL studies, and was the rate of sustained 
virological response (SVR), defined as viremia lower 
than 15 IU/mL 12 weeks after therapy cessation in all 
the patients who received at least one dose of the drug 
after randomization. The secondary endpoints were 
different across the ASTRAL studies and depended 
on the specific enrolled populations and randomiza-
tion. 
ASTRAL-1 showed HCV infection and liver 
damage up to compensated cirrhosis in patients with 
GTs 1-6 (excluding GT3), and a SVR rate of 99% in 
patients who received SOF/VEL for 12 weeks, which 
is a significantly higher rate than the 85% value which 
was the pre-specified performance target. None of the 
subjects who received a placebo obtained an SVR (9). 
The SVR rate was comparable among the dif-
ferent GTs (98% for GT1a, 99% for GT1b, 100% for 
GT2, 4, and 6, and 97% for GT5).
120/121 (99%) cirrhotic patients reached a SVR 
including 99.5% of experienced patients (9). Among 
non-cirrhotic patients 496/501 (99%) experienced a 
SVR (9). 
ASTRAL-2 was a specifically required study by 
the Food and Drug Administration as a separated 
trial (10). The results showed a SVR rate of 99% in 
patients who received SOF/VEL for 12 weeks com-
pared to 94% in those who underwent SOF plus RBV 
for 12 weeks. At the time the ASTRAL-2 study was 
performed, standard therapy showed a significant  im-
provement in efficacy (10). 
As reported in ASTRAL-3, HCV GT3 infected 
patients treated with SOF/VEL for 12 weeks reached 
a 95% SVR rate compared to 80% as shown by those 
receiving SOF plus RBV for 24 weeks, which is a 
highly significant difference in efficacy (p<0.001) (10). 
Considering non-cirrhotic GT3 patients, SOF/VEL 
led to SVR in 191/197 subjects (97%, while SOF plus 
RBV determined an SVR in 163/187 subjects (87%).
The SVR rate with all oral DAAs in decompen-
sated cirrhosis was lower than in patients with less ad-
vanced liver disease (10). 
The phase 3 ASTRAL-4 study aimed to evalu-
ate the efficacy of SOF/VEL in the difficult-to-treat 
HCV-infected population, showing an eradication 
rate of 83% after 12 weeks of SOF/VEL, 94% after 
12 weeks of SOF/VEL plus RBV, and 86% after 24 
weeks of SOF/VEL (11). The SVR rate obtained from 
the different SOF/VEL based regimens did not show 
any significant differences. However, in decompen-
sated cirrhosis caused by HCV GT3 infection, a SVR 
rate of 71% was previously reported (13) due to the 
fact that SOF/VEL plus RBV for 12 weeks resulted in 
85% of the SVR. 
The benefits of IFN-free therapy in advanced 
liver disease are still unclear. The secondary efficacy 
endpoints of ASTRAL-4 were linked to the improve-
ment of liver damage, as the CPT and MELD scores 
changed at week 12 after therapy cessation (11). The 
analysis of CPT and MELD scores was performed on 
250/267 patients; an improvement of CPT, compared 
to the baseline value, was observed in 47% of patients, 
and an improvement of MELD in 51% of those with 
a baseline value of less than 15, and in 81% of subjects 
with a MELD higher than 15. In general, such an im-
provement is due to a decrease in bilirubin levels and an 
increase in albumin levels (11). However, the long-term 
benefits on hepatic functions remain to be assessed. 
Two efficacy endpoints were established in the 
ASTRAL-5 study, which was dedicated to the special 
population of HCV/HIV co-infected subjects (12). 
The first efficacy endpoint was common in the other 
ASTRAL studies and showed 95% of SVR in 106 
HCV/HIV patients who underwent SOF/VEL for 12 
weeks. All of the patients with cirrhosis reached a SVR 
(100%) along with 94% of the black patients and 94% 
of the experienced patients.
The secondary endpoint was the assessment of the 
percentage of real virological failures in patients who 
had viremia lower than 15 IU/mL during treatment. 
In fact, among the 5/106 patients not included in the 
SVR group, only 2 patients were virological failures (at 
week 4 of post-treatment), while 2 were lost during the 
follow-up, and 1 withdrew consent (12).
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An integrated post-hoc analysis on antiviral ef-
ficacy considering the main Astral trials (Astral-1, -2 
and -3) has been recently performed (14). The SOF/
VEL treatment for 12 weeks in 1035 patients showed 
an overall SVR rate of 98% with an intention-to-treat 
analysis (Figure 2). The high efficacy was consistent 
across all genotypes, with only 2 virological relapse in 
GT1 and 11 in GT3 patients.
A retrospective analysis of efficacy results of SOF/
VEL for 12 weeks for GT1–6 in phase 3 trials stratified 
by fibrosis stage has been recently proposed (15). The 
authors pooled patients data from SOF/VEL registra-
tion trials (ASTRAL-1 - NCT02201940, ASTRAL-2 
NCT02220998, ASTRAL-3 NCT02201953) and 
SOF/VEL/VOX Polaris phase 3 studies (POLARIS-2 
NCT02607800, and POLARIS-3 NCT02639338), 
where SOF/VEL treatment was considered as com-
parative arm. 
Authors identified 1567 patients enrolled in the 
ASTRAL and POLARIS programs and a METAVIR 
category was assigned according to the FibroTest score 
(16). Demographics of the patient population strati-
fied according to fibrosis score are summarized in Ta-
ble 1 and Table 2.
The F0-F2 population was largely represented 
(n=887), with a mean age of 49 yrs, younger than F3 
and F4 groups (57 and 58 yrs, respectively), as expect-
ed. GTs distribution was homogeneous between the 
groups with GT1 as the most prevalent except for the 
cirrhotic subjects where 37% of patients was infected 
by GT3. F4 group showed a higher proportion of ex-
perienced patients (40%) when compared to patients 
with milder fibrosis (20% and 28% for F0-2 and F3, 
respectively).
In addition to the Intention-to-treat (ITT) 
analysis, that considered all patients who were rand-
omized and received ≥1 dose of assigned study drug, 
the Completer analysis was also performed, evaluating 
all patients who were randomized, completed assigned 
study treatment, and had HCV RNA data observed at 
post-treatment week 12 or imputed from a later time-
point.
SOF/VEL for 12 weeks was highly effective 
across all GTs regardless of degree of fibrosis as shown 
in Figure 3 and Figure 4 (15). Considering the Com-
pleter analysis, in the F0-F2 group almost all patients 
achieved an SVR (99.6%) with only 3 GT3 infected 
patients who relapsed out of 874 treated individuals 
(Figure 3). Similar high rates of response were reg-
istered also in patients with advanced fibrosis (F3: 
232/234 SVR, 99.1%) and with cirrhosis (F4: 431/443 
SVR, 97.2%) (Figure 4). In this latter group, high rates 
Figure 2. Integrated Intention To Treat Analysis of Efficacy from Astral 1-3: SVR12. SVR12: Sustained Virological Response 12; 
GT: Genotype; LTFU: Lost at Follow-Up; D/C: Discontinuation. Modified from (14).
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of SVR were obtained also in GT3 patients (154/163, 
94.4%) without the need for Ribavirin.
The ITT analysis showed minor differences, since 
only 16 patients out of 1567 were excluded from the 
Completer analysis (15). 
Safety across ASTRAL studies
Rate of adverse events (AEs) and treatment dis-
continuation because of AEs was the secondary end 
point of the ASTRAL-1 study (9). Treatment was in-
Table 1. Demographic features of F0-F2 patients, treated for 12 weeks, from the Integrated analysis (ASTRAL and Polaris studies)
Total n of F0-F2 patients  887
Mean age, y (range)  49 (18-79)
Male, n (%)  421 (47)
Mean BMI, kg/m2 (range)  26 (17-48)
HCV GT, n (%)  1a 205 (23)
 1b 102 (11)
 2 196 (22)
 3 227 (26)
 4 101 (11)
 5 24 (3)
 6 31 (3)
Baseline HCV RNA log10 IU/mL, mean (range)  6.3 (1.1-7.8)
Treatment Experienced, n (%)  177 (20)
F0, n (%)  337 (38)
F1, n (%)  160 (18)
F2, n (%)  390 (44)
Legend:  BMI: Body Mass Index; GT: genotype; IU: International Units
Table 2. Demographic features of F3 and F4 patients, treated for 12 weeks, from the Integrated analysis (ASTRAL and Polaris 
studies)
  F3 F4
Total n of patients  236 444
Mean age, y (range)  57 (33-81) 58 (34-82)
Male, n (%)  162 (69) 355 (80)
Mean BMI, kg/m2 (range)  28 (18-57) 28 (17-47)
HCV GT, n (%)  1a 67 (28) 107 (24)
 1b 26 (11) 48 (11)
 2 34 (14) 58 (37)
 3 77 (33) 164 (37)
 4 21 (9) 49 (11)
 5 5 (2) 5 (1)
 6 6 (3) 13 (3)
Baseline HCV RNA log10 IU/mL, mean (range)  6.3 (4.0-7.4) 6.2 (4.1-7.5)
Treatment Experienced, n (%)  66 (28) 176 (40)
Legend: BMI: Body Mass Index; GT: genotype; IU: International Units
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terrupted by 1 patient (<1%) in the SOF/VEL group 
and by 2 patients (2%) in the placebo group. Serious 
AEs occurred in 15 patients (2%) treated with SOF/
VEL and in none of the patients who received a pla-
cebo. Overall, AEs (mostly headache, nausea, fatigue 
and nasopharyngitis) were recorded in 78% of sub-
Figure 3. ASTRAL-1, -2, -3 and POLARIS-2, -3 combined retrospective analyses of efficacy in patients  with METAVIR F0-F2, 
treated with Sofosbuvir/Velpatasvir for 12 weeks. Patients were treatment naïve and treatment experienced (including PI-failure); 
SVR: Sustained Virological Response; GT: Genotype. Modified from (15).
Figure 4. ASTRAL-1, -2, -3 and POLARIS-2, -3 combined retrospective analyses of efficacy in patients with METAVIR F3 and 
F4, treated with Sofosbuvir/Velpatasvir for 12 weeks. Patients were treatment naïve and treatment experienced (including PI-failure); 
SVR: Sustained Virological Response; GT: Genotype. Modified from (15).
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jects who underwent SOF/VEL therapy, and in 77% 
of those in the placebo group, without any significant 
difference (9). 
In the ASTRAL-2 and ASTRAL-3 studies, a 
patient included in the ASTRAL-2 study interrupt-
ed treatment after the first pill due to anxiety and a 
headache (10). In ASTRAL-3, RBV was only discon-
tinued by 9 patients (3%) as a result of AEs. In the 
ASTRAL-2 study, the percentage of serious AEs was 
the same in those who received and those who did not 
receive RBV (1%); in the ASTRAL-3 study, 2% of 
subjects who did not receive RBV experienced seri-
ous AEs compared to 15% of those who received RBV. 
Considering both studies, AEs were generally frequent 
in patients who underwent RBV-including regimens 
and the types of AEs were typical of RBV (anemia, 
insomnia, irritability and coughing). Two ASTRAL-2 
patients died during the post-treatment follow-up and 
3 ASTRAL-3 patients died during treatment. All the 
deaths seemed to be due to causes unrelated to therapy 
or were categorized as unknown (10). 
As expected for the severe condition of the study 
population in terms of liver damage, the serious AEs 
rate was higher in the three groups of the ASTRAL-4 
study with hepatic encephalopathy and sepsis being 
the most frequent and serious AEs (11). For the same 
reason, the nine deaths that occurred during the study 
were thought to be unrelated to  treatment and were 
possibly ascribable to the end-stage of liver disease. 
Anemia was very common in 30% of patients who re-
ceived RBV, and was experienced at a different level 
of severity.
ASTRAL-5 had a proportion of patients who 
interrupted treatment due to AEs as a primary safety 
end-point (12). In fact, 71% of patients experienced at 
least one AE, which was serious in only 2 cases (2%) 
and led to therapy discontinuation in one case. An-
other patient interrupted therapy as a consequence 
of a mild adverse event (a single vomiting episode) at 
day 48 and reached SVR12 regardless. None of the 
patients died and in none of the cases, the ARV was 
modified (12).  
Pruritus was not observed in any patient of the 
ASTRAL studies among the AEs (9-12).
Overall, the SOF/VEL regimens demonstrated 
a very good safety profile in all the ASTRAL stud-
ies, which covered a wide range of the different fea-
tures that are typical of HCV-chronically infected 
patients. Nevertheless, in the case of other concomi-
tant treatments, caution is required in order to avoid 
drug-to-drug interactions (DDI) (17). SOF/VEL is 
not recommended for patients treated with amiodar-
one due to the risk of severe symptomatic bradycar-
dia if taken together (17). Other drugs reduce SOF/
VEL efficiency (antacids and proton pump inhibitors, 
some anticonvulsants, antimycobacterials, and chemo-
therapy topotecan) (17-19). However, the SOF/VEL 
regimen presents a very good DDI profile, which rep-
resents the best option in multi-treated patients with 
co-morbidities, in women of child-bearing potential, 
and in active drug users or in opioid substitution ther-
apy (19-21). This makes SOF/VEL regimen suitable 
also for patients using recreational drugs, generally not 
mentioned during the anamnestic evaluation.
SOF/VEL can also be administered in patients 
with mild or moderate renal impairment, even if it is 
not recommended for patients with more severe renal 
damage (eGFR\30 mL/min/1.73 m2). 
The tolerability of SOF/VEL for 12 weeks was 
retrospectively assessed by an integrated safety analysis 
in more than 1000 patients treated in the ASTRAL-1, 
ASTRAL-2, and ASTRAL-3 studies (22). As showed 
by Table 3, SOF/VEL was well tolerated in HCV-in-
fected patients with similar incidence and severity as in 
placebo treated subjects (Table 3). As reported in Ta-
ble 4, the most common AEs emerging in SOF/VEL 
group from the integrated analysis were headache, fa-
tigue, nausea, and nasopharyngitis, whose incidence 
was similar in placebo undergoing patients (Table 4).
Health-related quality of life and work productivity 
analysis in the ASTRAL studies
Patients with chronic HCV infection, usually 
have a poor health-related quality of life and impaired 
work productivity (23, 24). The patients reported out-
comes are directly described by the patient and pertain 
to the patient’s health, quality of life, or functional sta-
tus associated with health care or treatment. The effect 
of SOF/VEL on PROs in HCV-patients included in 
the ASTRAL studies was performed (25, 26), and a 
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comparative analysis between patients with and with-
out cirrhosis was also conducted (27, 28). 
The analysis performed on the ASTRAL-1 pa-
tient groups showed that patients treated with SOF/
VEL experienced a significant improvement in PROs 
during treatment and after SVR. In the placebo group, 
only one PRO improved by week 4 of treatment, and 
no further improvements were noted (25). 
ASTRAL-2 and ASTRAL-3 populations were 
analyzed with regard to PROs in a dedicated study 
with a total of 818 HCV patients (25, 26). As previ-
ously mentioned, the overall rates of all adverse events 
were lower in the RBV-free SOF/VEL group (all 
p<0.03) and, therefore, patients who received RBV-
free SOF/VEL regimens, reported significantly higher 
PRO scores during treatment compared to those who 
received the RBV-containing regimen (SOF plus 
RBV) (25, 26). At post-treatment week 12, changes 
from baseline levels were no longer different between 
the two treatment arms (25, 26). 
Finally, a comparative analysis of PROs during 
and after SOF/VEL treatment in HCV patients with 
and without cirrhosis, from ASTRAL studies (1 to 4) 
was performed by Younossi and co-workers (27, 28). 
As expected, baseline PROs were lower in patients 
with cirrhosis, but, during SOF/VEL treatment and 
after reaching the SVR, subjects with and without cir-
rhosis experienced a significant improvement in the 
scores (27, 28).
In general, the administration of SOF/VEL pro-
duced a significant improvement in patients’ quality of 
life, resulting in a benefit for the patients going beyond 
the SVR, as demonstrated by the PROs analysis of pa-
tients’ perception of the treatment (25-28). 
Conclusions
Data from phase III clinical trials on Sofosbuvir/
Velpatasvir demonstrated that this antiviral combina-
tion addresses many unmet medical challenges. SOF/
VEL make HCV treatment easier as the same therapy 
schedule are suitable for all the genotypes, irrespec-
tive of the fibrosis stage, making SOF/VEL a pan-
genotypic and pan-fibrotic regimen. The presence of 
SOF warrantees high efficacy and minimal DDI and 
the combination with VEL, a last generation NS5A 
inhibitor, makes this regimen the standard of care for 
the treatment of chronic HCV infection. 
The single-pill, once-a-day posology improves the 
adherence to the therapy and the absence of lactose 
and gluten make it suitable to patients intolerant or 
allergic to these substances. 
Table 3. Retrospective integrated analysis of data from 1,035 
SOF/VEL for 12 Weeks patients and control/placebo patients 
in ASTRAL-1, -2, and -3
Patients, n (%) SOF/VEL Placebo
 12 weeks 12 weeks
 N=1035 N=116
AEs 821 (79) 89 (77)
Grade 3 or 4 AEs 33 (3) 1 (<1)
SAEs 23 (2)* 0
AE leading to treatment D/C 2 (<1)^ 2(2)
Death 3 (<2)** 0)
Legend: SOF: Sofosbuvir; VEL: Velpatasvir; AEs: Adverse 
Events; SAEs: Severe Adverse Events; D/C: Discontinuation; 
*No SAE was assessed as related to SOF/VEL; **None were 
assessed as related to study treatment; ̂ Two subjects D/C SOF/
VEL for AEs; (1 D/C day 1 due to difficulty concentrating, 
headache, and anxiety and 1 D/C day 13 of due to anxiety)
Table 4. More frequent adverse events from the retrospective 
integrated safety analysis of data from 1,035 SOF/VEL for 12 
Weeks patients and control/placebo patients in ASTRAL-1, -2, 
and -3
Patients, n (%) SOF/VEL Placebo
 12 weeks 12 weeks
 N=1035 N=116
Headache 296 (29) 33 (28)
Fatigue 217 (21) 23 (20)
Nausea 135 (13) 13 (11)
Insomnia 87 (8) 11 (9)
Nasopharyngitis 121 (12) 12 (10)
Cough 57 (6) 4 (3)
Irritability 49 (5) 4 (3)
Pruritus 33 (3) 5 (4)
Dyspepsia 33 (2) 4 (3)
Legend: SOF: Sofosbuvir; VEL: Velpatasvir; severe adverse 
events were rare in SOF/VEL-treated patients, with headache, 
anxiety, and acute myocardial infarction occurring >1 patient 
(both cases of acute myocardial infarction were assessed as not 
related to SOF/VEL treatment by the investigators)
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SOF/VEL is a RBV-free regimen and in naïve 
non-cirrhotic patients attains SVR rates up to 100% 
in all genotypes. In decompensated cirrhotic patients, 
SOF/VEL, with the addition of RBV, resulted in 94% 
of SVR.
Actually, SOF/VEL is safe and effective on all-
stages of liver disease, including decompensated cir-
rhosis, thanks to the absence of protease inhibitors 
As a pangenotypic and pan-fibrosis regimen, it is 
conceivable that SOF/VEL will simplify, or perhaps 
eliminate, the pre-treatment assessments and on treat-
ment monitoring that represent a barrier to treatment 
access in several countries. Considering the character-
istics of SOF/VEL, this regimen can be considered the 
ideal partner in the path to HCV eradication.
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